Using cerebrospinal fluid from living patients, researchers have identified specific proteins and genetic pathways involved ...

EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...

and are at increased risk of developing Alzheimer’s disease. Those with one copy are at increased risk too. Leqembi, which is ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...